CURX: יתרות מזומנים למניה אחת Curanex Pharma

Curanex Pharmaceuticals Inc (CURX) is developing innovative targeted drug delivery methods for the therapy of liver and gastrointestinal pathologies. The strategy is based on creating highly bioavailable drugs that improve current medical standards for treating chronic disorders. Cash per share reflects the absence of a stable operating cash flow due to the clinical testing stage, with the parameter stabilizing at 1.02.
פילוחי מדדים מקיפים ואנליטיקה עבור Curanex (CURX)

Curanex Pharmaceuticals Inc (CURX) focuses on developing gastrointestinal therapies, which entails a prolonged development period without operating profit. This metric is calculated by dividing total liquid assets by the number of shares outstanding. It determines the issuer's actual solvency and its ability to fund R&D processes. A high level of reserves minimizes bankruptcy risks but may indicate inefficient capital allocation. The annual trend of cash per share clearly confirms the financial stability of Curanex Pharmaceuticals Inc (CURX) given its narrow therapeutic profile.